Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients

Archives of General Psychiatry

Volumn 54, Issue 3, 1997, Pages 214-222

  Marangell, Lauren B ^a,b   George, Mark S ^c   Callahan, Ann M ^a,d   Ketter, Terence A ^a,f   Pazzaglia, Peggy J ^a,g   L'Herrou, Todd A ^e   Leverich, Gabriele S ^a   Post, Robert M ^a,h  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Electronic Village Systems   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; HYDROCORTISONE; LITHIUM CARBONATE; MONOAMINE OXIDASE INHIBITOR; PROTIRELIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; HYPERHIDROSIS; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; INTRATHECAL DRUG ADMINISTRATION; MALE; PSYCHOMOTOR RETARDATION; RESTLESSNESS; SHIVERING; SUICIDE;

EID: 0030968504     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830150034007     Document Type: Article

References (45)

1. Breese GR, Mueller RA, Mallman RB, Frye GD. Effects of TRH on central nervous system functions. In: Liss AR, ed. The Role of Peptides and Amino Acids as Neurotransmitters. New York, NY: Alan R Liss Inc; 1981:99-116.
2. Loosen PT. TRH: behavioral and endocrine effects in man. Prog Nauropsychopharmacol Biol Psychiatry. 1988;12(suppl):S87-S117.
3. Plotnikoff NP, Prange AJ, Breese GR, Anderson MS. Enhancement of DOPA activity by a hypothalamic hormone, thyrotropin releasing hormone, TRH. Science. 1972;178:417-418.
4. Manaker S, Eichen A, Winokur A, Rhodes CH, Rainbow TC. Autoradiographic localization of thyrotropin releasing hormone receptors in human brain. Neurology. 1986;36:641-646.
5. Stanton TL, Beckman AL, Winokur A. Thyrotropin-releasing hormone effects in the central nervous system: dependence on arousal state. Science. 1981;214:678-681.
6. Maurelli M, Tartara A, Marchioni E, Savoldi F. The spectrum of actions of thyrotropin-releasing hormone on the CNS: a polygraphic study on rabbits. Neurosci Lett. 1984;46:85-90.
7. Rips R, Boschi G. Interactions between TRH and catecholamines serotonin, acetylcholine and other neuromodulators. Prog Neuroendocrinol. 1985;1:261-271.
8. Crespi F, Keane PE, Morre M. In vivo evaluation by differential pulse voltammetry of the effect of thyrotropin-releasing hormone (TRH) on dopaminergic and serotoninergic synaptic activity in the striatum and nucleus accumbens of the rat. Exp Brain Res. 1986;62:329-334.
9. Metcalf G. Regulatory peptides as a source of new drugs: the clinical prospects for analogues of TRH which are resistant to metabolic degradation. Brain Res Rev. 1982;4:389-408.
10. Meyerhoff JL, Bates VE, Kubek MJ. Elevated TRH levels in pyriform cortex after partial and fully generalized kindled seizures. Brain Res. 1990;525:144-148.
11. Kubek MJ, Meyerhoff JL, Hill TG, Norton JA, Sattin A. Effects of subconvulsive and repeated electroconvulsive shock on thyrotropin-releasing hormone in rat brain. Life Sci. 1985;36:315-320.
12. Kubek MJ, Sattin A. Effect of electroconvulsive shock on the content of thyrotropin-releasing hormone in rat brain. Life Sci. 1984;34:1149-1152.
13. Sattin A, Hill TG, Meyerhoff JL, Norton JA, Kubek MJ. The prolonged increase in thyrotropin-releasing hormone in rat limbic forebrain regions following electroconvulsive shock. Regul Pept. 1987;19:13-22.
14. Marangell LB, George MS, Bissette G, Pazzaglia P, Huggins T, Post RM. Carbamazepine increases CSF thyrotropin-releasing hormone in affectively ill patients. Arch Gen Psychiatry. 1994;51:625-628.
15. Itil TM, Patterson CD, Poivan N, Bigelow A, Bergey B. Clinical and CNS effects of oral and IV thyrotropin-releasing hormone in depressed patients. Dis Nerv Sys. 1975;2:529-536.
16. Prange AJ Jr, Lara PP, Wilson IC, Alltop LB, Breese GR. Effects of thyrotropin-releasing hormone in depression. Lancer. 1972;2:999-1002.
17. Bassiri RW, Utiger RD. Metabolism and excretion of exogenous thyrotropin-releasing hormone in humans. J Clin Invest. 1973;52:1616-1619.
18. Brooks BR, Kalin N, Beaulieu DA, Barksdale C, Sufit RL, Dills DG. Thyrotropin releasing hormone uptake into serum and cerebrospinal fluid following intravenous or subcutaneous administration. Neurol Res. 1988;10:236-238.
19. Munsat TL, Taft J, Jackson IMD. Pharmacokinetics of intrathecal thyrotropin-releasing hormone. Neurology. 1987;37:597-601.
20. Di Chiro G. Movement of the cerebrospinal fluid in human beings. Nature. 1964;204:290-291.
21. Stober T, Schimrigk K, Dietzsch S, Thielen T. Intrathecal thyrotropin-releasing hormone therapy of amyotrophic lateral sclerosis. J Neurol. 1985;232:13-14.
22. Munsat TL, Taft J, Kasdon D. Intrathecal thyrotropin-releasing hormone in amyotrophic lateral sclerosis. Neurol Clin. 1987;5:159-170.
23. Munsat TL, Taft J, Jackson IM, Andres PL, Hollander D, Skerry L, Ordman M, Kasdon D, Finison L. Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system. Neurology. 1992;42:1049-1053.
24. Vigneri R, Pezzino V, Filetti S, Squatrito S, Corso A, Maricchiolo M, Polosa P, Scapagnini U. Thyrotropin and proiactin response to intraspinal TRH administration in man. Neuroendocrinology. 1977;23:171-180.
25. Coffey YJ, Cahill D, Steers W, Parks TS, Ordla J, Meythaler J, Herman R, Shelter AG, Levy R, Gill B. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg. 1993;78:226-232.
26. Loubser PG, Narayan RK, Sandin KJ, Donovan WH, Russell KD. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia. 1991;29:48-64.
27. Hasle H, Helgestad J, Christensen JK, Jacobsen BB, Kamper J. Prolonged intrathecal chemotherapy replacing cranial irradiation in high-risk acute lymphatic leukaemia: long-term follow up with cerebral computed tomography scans and endocrinological studies. Eur J Pediatr. 1995;154:24-29.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
29. Post RM, Roy-Byrne PP, Uhde TW. Graphic representation of the life course of illness in patients with affective disorder. Am J Psychiatry. 1988;145:844-848.
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;12:56-62.
31. Beck AT, Ward C, Mendelson M, Mock J, Erbough J. An Inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
32. Abrams R, Taylor MA, Faber R, Ts'o TO, Williams RA, Almy G. Bilateral versus unilateral electroconvulsive therapy: efficacy in melancholia. Am J Psychiatry. 1983;140:463-465.
33. Strouse TB, Szuba MP, Baxter Jr LR. Response to sleep deprivation in three women with postpartum psychosis. Am J Clin Psychiatry. 1992;53:204-206.
34. Bunney WEJ, Hamburg DA. Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry. 1963;9:280-294.
35. Beck AT, Kovacs M, Weissman A. Assessment of suicidal Intention: the scale for suicide ideation. J Consult Clin Psychol. 1979;47:343-352.
36. Banki CM, Bissette G, Arato M, Nemeroff CB. Elevation of immunoreactive CSF TRH in depressed patients. Am J Psychiatry. 1988;145:1526-1531.
37. Kirkegaard C, Faber J, Hummer L, Rogowski P. Increased levels of TRH in cerebrospinal fluid from patients with endogenous depression. Psychoneuroendocrinology. 1979;4:227-235.
38. Roy A, Wolkowitz OM, Bissette G, Nemeroff CB. Differences in CSF concentrations of thyrotropin-releasing hormone in depressed patients and normal subjects: negative findings. Am J Psychiatry. 1994;151:600-602.
39. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorders. Am J Psychiatry. 1992;149:999-1010.
40. Kellner CH, Post RM, Putnam F, Cowdry R, Gardner D, Kling MA, Minichiello MD, Trettau JR, Coppola R. Intravenous procaine as a probe of limbic system activity in psychiatric patients and normal controls. Biol Psychiatry. 1987;22:1107-1126.
41. Ketter TA, Andreason PJ, George MS, Lee C, Gill DS, Parekh PI, Willis MW, Herscovitch P, Post RM. Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences. Arch Gen Psychiatry. 1996;53:59-69.
42. Huey LY, Janowsky DS, Mandell AJ, Judd LL, Pendery M. Preliminary studies on the use of TRH in manic states, depression, and the dysphoria of alcohol withdrawal. Psychopharmacol Bull. 1975;11:24-27.
43. Lazorthes Y, Sallerin-Caute B, Verdie JC, Bastide R. Advances in drug delivery systems and applications in neurosurgery. Adv Tech Stand Neurosurg. 1991;18:143-192.
44. Chambers FA, MacSullivan R. Intrathecal morphine in the treatment of chronic intractable pain. Ir J Med Sci. 1994;163:318-321.
45. Callahan AM, Frye MA, Marangell LB, George MS, Ketter TA, Kimbrell TA, L'Herrou T, Pazzaglia PJ, Post RM. Differential mood and endocrine effects of Intravenous vs intrathecal TRH. Biol Psychiatry. 1995;37:609. Abstract.